Drug intelligence / Profile preview

Shingrix + Boostrix

Development stage: Approved
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Shingrix + Boostrix refers to the concurrent administration of two vaccines developed by GSK: Shingrix (Herpes Zoster Vaccine, Recombinant, Adjuvanted) and Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed). Shingrix is a non-live, recombinant subunit vaccine containing the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, designed to prevent herpes zoster (shingles) in adults. Boostrix is a Tdap vaccine used for active booster immunization against tetanus, diphtheria, and pertussis. Clinical trials, such as NCT02114359, have evaluated the safety and immunogenicity of co-administering these vaccines to provide comprehensive protection against these four diseases in a single visit for adults aged 50 and older.

Brand names: ShingrixBoostrix
Other names: Boostrix-GlaxoSmithKline-Herpes ZosterShingrix and Boostrix Co-administrationHerpes Zoster vaccine recombinant adjuvanted + Tdap vaccine

Targets

PRN (Pertactin)TLR4 (Toll-like receptor 4)Diphtheria toxinFHA (Filamentous hemagglutinin)gE (VZV glycoprotein E)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Shingrix + Boostrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shingrix + Boostrix.

Explore the full profile